NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC

Exclusion Criteria

• •1. Postoperative pathology confirms cholangiocarcinoma, sarcomatoid HCC, combined HCC-ICC, or fibrolamellar carcinoma.
• •2. Presence of portal vein, hepatic vein, or bile duct tumor thrombus.
• •3. History of other malignancies (except cured carcinoma in situ of cervix, basal cell carcinoma, or squamous cell skin carcinoma).
• •4. Evidence of residual lesion, recurrence, or metastasis during preoperative assessment; or postoperative pathology confirming lymph node metastasis or positive margins.
• •5. Moderate to severe ascites requiring therapeutic paracentesis/drainage, or Child-Pugh score \> 7 (except for small amount of ascites on imaging without clinical symptoms).
• •6. Uncontrolled or moderate/large amount of pleural effusion or pericardial effusion.
• •7. Severe cardiac, pulmonary, or renal dysfunction.
• •8. Ruptured HCC requiring emergency surgery.
• •9. Patient or family unable to understand the study conditions and objectives.